Zacks Investment Research upgraded shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) from a hold rating to a buy rating in a research note issued to investors on Friday, Zacks.com reports. They currently have $182.00 price target on the biopharmaceutical company’s stock.
According to Zacks, “GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom. “
GWPH has been the subject of several other reports. Piper Jaffray Companies upped their target price on shares of GW Pharmaceuticals PLC- from $185.00 to $210.00 and gave the stock an overweight rating in a research report on Tuesday, May 7th. Oppenheimer downgraded shares of GW Pharmaceuticals PLC- from an outperform rating to a market perform rating and set a $195.00 price target for the company. in a research note on Wednesday, May 8th. Cantor Fitzgerald reissued an overweight rating and issued a $229.00 price target (up from $196.00) on shares of GW Pharmaceuticals PLC- in a research note on Tuesday, May 7th. Morgan Stanley reissued a buy rating on shares of GW Pharmaceuticals PLC- in a research note on Tuesday, April 9th. Finally, CIBC raised shares of GW Pharmaceuticals PLC- from a market perform rating to an outperform rating in a research note on Tuesday, May 7th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and twelve have issued a buy rating to the stock. GW Pharmaceuticals PLC- presently has a consensus rating of Buy and a consensus price target of $203.91.
NASDAQ:GWPH traded down $1.97 during midday trading on Friday, hitting $155.72. The company had a trading volume of 418,643 shares, compared to its average volume of 320,719. GW Pharmaceuticals PLC- has a 52-week low of $90.14 and a 52-week high of $196.00. The stock has a fifty day simple moving average of $169.37. The firm has a market cap of $4.90 billion, a P/E ratio of -14.75 and a beta of 2.25. The company has a debt-to-equity ratio of 0.03, a current ratio of 7.81 and a quick ratio of 7.19.
GW Pharmaceuticals PLC- (NASDAQ:GWPH) last announced its earnings results on Monday, May 6th. The biopharmaceutical company reported ($1.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.48) by $0.80. GW Pharmaceuticals PLC- had a negative net margin of 458.79% and a negative return on equity of 45.75%. The company had revenue of $39.20 million during the quarter, compared to analyst estimates of $12.32 million. During the same period in the previous year, the business earned ($3.12) earnings per share. The firm’s quarterly revenue was up 1189.5% compared to the same quarter last year. On average, sell-side analysts predict that GW Pharmaceuticals PLC- will post -5.41 earnings per share for the current year.
In other news, insider Adam D. George sold 258,324 shares of the company’s stock in a transaction dated Tuesday, May 7th. The shares were sold at an average price of $16.10, for a total transaction of $4,159,016.40. Following the completion of the transaction, the insider now directly owns 268,324 shares of the company’s stock, valued at $4,320,016.40. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Justin D. Gover sold 202,224 shares of the company’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $15.24, for a total transaction of $3,081,893.76. Following the transaction, the chief executive officer now directly owns 743,765 shares of the company’s stock, valued at $11,334,978.60. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,506,720 shares of company stock valued at $23,046,711. Insiders own 3.60% of the company’s stock.
Large investors have recently modified their holdings of the company. Horan Capital Advisors LLC. bought a new position in shares of GW Pharmaceuticals PLC- during the first quarter valued at about $25,000. Kavar Capital Partners LLC bought a new position in GW Pharmaceuticals PLC- in the second quarter worth about $26,000. Exane Derivatives bought a new position in GW Pharmaceuticals PLC- in the first quarter worth about $28,000. TCG Advisors LP bought a new position in GW Pharmaceuticals PLC- in the first quarter worth about $29,000. Finally, Institutional & Family Asset Management LLC bought a new position in GW Pharmaceuticals PLC- in the first quarter worth about $31,000. 78.95% of the stock is owned by hedge funds and other institutional investors.
GW Pharmaceuticals PLC- Company Profile
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.
Read More: New Google Finance Tool and Screening Stocks
Get a free copy of the Zacks research report on GW Pharmaceuticals PLC- (GWPH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.